Singapore markets closed

Straits Times Index
3,332.80
-10.55(-0.32%)
Nikkei
39,583.08
+241.54(+0.61%)
Hang Seng
17,718.61
+2.14(+0.01%)
FTSE 100
8,164.12
-15.56(-0.19%)
Bitcoin USD
60,644.73
-1,148.23(-1.86%)
CMC Crypto 200
1,264.21
-19.62(-1.53%)

HALO Mar 2025 40.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

13.50

0.00

(0.00%)

As of 11:39AM EDT. Market open.

Zacks
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR Newswire
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.
Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...